DISCO Pharmaceuticals is a biopharmaceutical company focused on redefining cancer drug discovery by developing novel cancer-selective cell surface targets for the creation of innovative therapeutics.

DISCO Pharmaceuticals

DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.

DISCO Pharmaceuticals GmbH

Meet us at the DISCO!

The DISCO Pharmaceuticals GmbH website that is. Meet the team and read more about what we do and how we will transform the landscape of cancer care.

www.discopharma.de

Keep up to date with what's happening at DISCO by following us at DISCO Pharmaceuticals GmbH on LinkedIn and @DISCOPharma on #X

#surfaceome #proteomics #optoproteomics #drugdiscovery #biotech

Introducing DISCO Pharmaceuticals GmbH! The surfaceome company. 

Translating over a decade of research, DISCO launches today with its revolutionary surface proteomics platform to identify novel cancer targets on the cell surface at scale, and to develop first in class drugs. 

DISCO's mission is to improve treatment options for patients living with cancer by unleashing the full potential of targeted cancer therapies.  

Find out more: https://bit.ly/48qI8Fz

#surfaceome #proteomics #optoproteomics #drugdiscovery #biotech

Metric
Company Name	DISCO Pharmaceuticals
Symbol
MSH ID	DE:DISCOPHARMA
Market	PRIVATE
Sector	Healthcare
Industry	Biopharmaceuticals
Country	DE
Stage	Seed
Employee Count
Website	discopharma.de
LinkedIn	disco-pharmaceuticals-gmbh
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	88
Web Traffic Growth	-0.34
Valuation
Raised Capital	21.76M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

DE:DISCOPHARMA

DISCO Pharmaceuticals

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue